Anonymous20 days ago
A landmark Phase III clinical trial called PRIMARY2, presented at the European Association of Urology Congress in London on March 13, 2026, has demonstrated that PSMA PET/CT scanning — which makes prostate cancer cells glow on imaging — can safely halve the number of men who need invasive biopsies while slashing overdiagnosis of clinically insignificant cancers by more than half. The trial of 660 high-risk Australian men found that the imaging-first strategy achieved 49% biopsy avoidance without compromising detection of clinically significant disease, offering a transformative new pathway for the world's most commonly diagnosed male cancer.